Clinical trial
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer…
NCT00312988 · North Eastern German Society of Gynaecological Oncology, Other · Completed
Key facts
| NCT number | NCT00312988 |
|---|---|
| Title | Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy |
| Official title | Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs. Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer |
| Lead sponsor | North Eastern German Society of Gynaecological Oncology, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Hycamtin, Gemcitabine |
| Enrollment | 450 |
| Start date | Jan 1, 2000 |
| Completion | Dec 1, 2009 |
| First posted | Apr 11, 2006 |
| Last update posted | Apr 11, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: